InnoCare Pharma Eulerpool Nyheter

InnoCare Pharma Eulerpool News

InnoCare Pharma Aksje Nyheter

InnoCare Pharma blir fulgt av mange journalister og investorer over hele verden. De nyeste InnoCare Pharma nyhetene presenterer vi her.

• ·

  Yahoo
  InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
• ·

  Yahoo
  InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
• ·

  Yahoo
  Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024
• ·

  Yahoo
  InnoCare Releases 2024 Interim Results and Business Highlights
• ·

  Yahoo
  British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents
• ·

  Yahoo
  InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
• ·

  Yahoo
  InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
• ·

  Yahoo
  Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress
• ·

  Yahoo
  InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
• ·

  SeekingAlpha
  Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal